EZN-3008

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEZN-3008
Drug Alias NamePEG C1 esterase inhibitorPegylated anti-TNF-α antibodyPegylated C1 esterase inhibitorPegylated interferon-β-1b - EnzonEZN-3008
ClassificationBiologics
Mechanisms of ActionComplement C1r inhibitorsImmunosuppressantsImmunomodulators +[4] 
TargetsComplement C1sComplement C1r
Therapy Area/IndicationsAutoimmune DiseasesAngioedemas, HereditaryMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEnzon Pharmaceuticals IncBelrose Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBelrose PharmaEnzon Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesAngioedemas, HereditaryMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A